Clinical Trials Search
Clinical Trial 20286
Cancer Type: Gastrointestinal Tumor
Study Type: Treatment
NCT#: NCT03972488
Phase: Phase III
Prinicipal Investigator: Jonathan Strosberg
Study Title
A Phase III Multi-Center, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET
Summary
Objective
Primary Objective: To demonstrate that Lutathera is superior to active comparator in delaying the time-to-first occurrence of progression or death (PFS) as first line treatment Key Secondary Objectives: To demonstrate the superiority of Lutathera, compared to active comparator, in terms of objective response. To demonstrate the superiority of Lutathera, compared to active comparator, in terms of time to deterioration in selected QoL items/scales
Therapies
Medications
177Lu-DOTA0-Ty3-Octreotate (Lutathera); Lutathera (); octreotide LAR ()
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.